Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Sweden's Vitrolife Q2 net income rises, helped by one-time gains

Sweden's Vitrolife Q2 net income rises, helped by one-time gains


Overview

  • Sweden reproductive health device maker's Q2 revenue fell 1% in local currencies, down 2% in SEK

  • Q2 adjusted EBITDA margin rose to 34.4%, helped by one-time effects and currency gains

  • Net income and EPS increased yr/yr despite lower revenue


Outlook

  • Vitrolife did not provide specific guidance or outlook for future periods in the press release


Result Drivers

  • ONE-TIME EFFECTS - Profitability was positively affected by a VAT accrual reversal and currency revaluation in operating expenses

  • PRODUCT MIX - Modest growth in consumables and technologies offset by decline in genetics sales

  • EXITED BUSINESSES - Organic growth was 1% in local currencies excluding exited NACE and GDPX product lines


Company press release: ID:nMFN97VFfD


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

SEK 857 mln

Q2 EPS

SEK 0.95

Q2 Net Income

SEK 129 mln

Q2 EBITDA

SEK 295 mln

Q2 EBITDA Margin

34.40%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Vitrolife AB is SEK131.00, about 50.1% above its July 15 closing price of SEK87.30

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 22 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Vitrolife AB

See all news